The pathogenic role of AVP in ADPKD was confirmed with the finding that V2R antagonists (V2RA) were able to reduce renal cAMP and disease progression in animal models [56] and then in ADPKD human disease [57]. The gene discussed is AVP; the disease is autosomal dominant polycystic kidney disease.